OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases

The companies aim to expand treatment options for millions living with metabolic disorders

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India

IIT Roorkee unveils cutting-edge molecular medicine facility

The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics

DrStore partners with TatvaCare to revolutionize diabetes & metabolic care in India

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform

Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases

Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist

Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases